Skeletal Complications after Renal Transplantation

Julian B.A. , Quarles L.D. , Niemann K.M.W. . Musculoskeletal complications after renal transplantation: Pathogenesis and treatment. Am J Kidney Dis 1992; 2: 99–120.

Rostaing L. , Moreau -Gaudry X. Changes in blood pressure and renal function following subtotal parathyroidectomy in renal transplant patients presenting with persistent hypercalcemic hyperparathyroidism. Clin Nephrol 1977; 4: 248–54.

Conference report. Consensus development conference: diagnosis, prophylaxis and treatment of osteoporosis. Am J Med 1993; 94: 646–50.

Julian B.A. , Laskow D.A. , Dubovsky J. , Dubovski E.V. , Curtis J.J. , Quarles L.D. . Rapid loss of vertebral mineral density after transplantation. N Engl J Med 1991; 325: 544–50.

Wolpaw T. , Deal C.L. , Fleming-Brooks S. , Bartucci M.R. , Schulak J. , Hricik D.E. . Factors influencing vertebral bone density after renal transplantation. Transplantation 1994; 58: 1186–9.

Almond M.K. , Kwan J.T. , Evans K. , Cunnigham J. . Loss of regional bone mineral density in the first 12 months following renal transplantation. Nephron 1994; 66: 52–7.

Aroldi A. , Tarantino A. , Montagnino G. , Cesana B. , Cocucci C. , Ponticelli C. . Effects of three immunosuppressive regimens on vertebral bone density in renal transplant recipients. A prospective study. Transplantation 1997; 63: 380–6.

Elli A. , Rivolta R. , Quarto di Palo F. A randomized trial of deflazacort versus 6-methylprednisolone in renal transplantation -immunosuppressive activity and side effects. Transplantation 1993; 55: 209–11.

Gennari C. , Imbimbo B. . Effects of prednisone and deflazacort on vertebral bone mass. Calcif Tissue Int 1985; 37: 592–3.

Stewart P.J. , Green O.C. , Stern PH: Cyclosporine A inhibits calcemic hormone-induced bone resorption in vitro. J Bone Miner Res 1986, 1: 285–91.

Movsowitz C. , Epstein S. , Fallon M. Cyclosporine-A in vivo produces severe osteopenia in the rat: Effect of dose and duration of administration. Endocrinology 1988 123: 2571–7.

Loertscher R. , Thiel G. , Harder F. , Brunner F.P. Persistent elevation of alkaline phosphatases in cyclosporine-treated renal transplant recipients. Transplantation 1983; 36: 115.

Romero D.F. , Buchinsky F.J. , Rucinski B. Rapamycin: a bone sparing immunosuppressant? J Bone Miner Res 1995; 10: 760–8.

Morris R.E. . Rapamycins: Antifungal, antitumor, anti proliferative, and immunosuppressive macrolides. Transplantation Reviews 1992; 6: 39–87.

Ettinger B. , Genant H.K. , Cann C.E. . Long-term estrogen replacement therapy prevents bone loss and fractures. Ann Intern Med 1985; 102: 319–24.

Gallagher JC , Riggs B.L. . Action of 1,25-dihydroxyvitamin D3 on calcium balance and bone turnover and its effect on vertebral fracture rate. Metabolism 1990; (suppl 1): S30–4.

Alicia J.F. , Vaswani A. , Yeh J.K. , Ellis K , Yasumura S. , Cohn S.H. . Calcitriol in the treatment of post menopausal osteoporosis. Am J Med 1988; 84: 4018.

Ott S.M. , Chesnut CH III . Calcitriol treatment is not effective in postmenopausal osteoporosis. Ann Intern Med 1989; 110: 267–74.

Sambrook P. , Birmingham J. , Kelly P. Prevention of corticoid osteoporosis: a comparison of calcium, calcitriol and calcitonin. N EngI J Med 1993; 328: 1747–52.

Overgaard K. , Hansen M.A. , Jensen S.B. , Christiansen C. . Effect of salcalcitonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study. BMJ 1992; 305: 556–61.

Ringe J.D. , Welzel D. . Salmon calcitonin in the therapy of corticoid-induced osteoporosis. Eur J Clin Pharmacol 1987; 33: 35–9.

Bohning W. , Ringe J.D. . Intranasal calcitonin in steroid dependent chronic obstructive pulmonary disease (COPD. to prevent bone mass decrease: a one year controlled and randomized trial (abstract 597)1990, 3rd Int Symp Osteoporosis.

Adachi J. , Bensen W. , Brown J. Intermittent etidronate therapy to prevent corticosteroid induced osteoporosis. N Engl J Med 1997; 337: 382–421.

Black D.M. , Cummings SR , Karpf DB . Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Trial Research Group, Lancet 1996; 348: 1535–41.

bis Thie baud D. , Kriegbaum H. , Huss H. Intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. Osteoporosis 1996; 1: 321–5.

Harrington K.D. , Murray W.R. , Kountz S.L. Avascular necrosis of bone after renal transplantation. J Bone Joint Surg Am 1971; 53: 203–15.

Pierides A.M. , Simpson W. , Stainsby D. Avascular necrosis of bone following renal transplantation. Q J Med 1975; 44: 459–80.

Vincenti F. , Hattner R. , Amend W.J. Jr. . Decreased secondary hyperparathyroidism in diabetic patients receiving hemodialysis. J Am Med Assoc 1981; 245: 930–3.

Parfrey P.S. , Farge D. , Parfrey N.A. The decreased incidence of aseptic necrosis in renal transplant recipients - A case control study. Transplantation 1986; 41: 182–7.

Elmstedt E: Avascular bone necrosis in the renal transplant patient. Clin Orthop 1981; 158: 149–57.

Slatopolsky E. , Martin K. . Glucocorticoids and renal transplant osteonecrosis. Adv Exp Med Biol 1984; 171: 353–9.

Warner J.J.P. , Philip J.H. , Brodsley G.L. Studies of nontraumatic osteonecrosis. Clin Orthop 1987; 225: 104–27.

Brazil M. , Linderer R.J. , Dickhans M.J. Aseptic hip necrosis after renal transplantation. Arch Surg 1986; 121: 803–5.